NASDAQ:ALNY Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $225.02 -6.35 (-2.74%) (As of 01/30/2023 03:36 PM ET) Add Compare Share Share Today's Range$224.25▼$231.4850-Day Range$204.79▼$241.3152-Week Range$117.58▼$242.97Volume335,972 shsAverage Volume711,846 shsMarket Capitalization$27.68 billionP/E RatioN/ADividend YieldN/APrice Target$239.84 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Alnylam Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.68 Rating ScoreUpside/Downside5.4% Upside$239.84 Price TargetShort InterestBearish4.62% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.51Based on 23 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($9.64) to ($6.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 starsMedical Sector1006th out of 1,049 stocksPharmaceutical Preparations Industry492nd out of 514 stocks 1.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.68, and is based on 13 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $239.84, Alnylam Pharmaceuticals has a forecasted upside of 5.4% from its current price of $227.63.Amount of Analyst CoverageAlnylam Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.62% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 1.9 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Alnylam Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($9.64) to ($6.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -23.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -23.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 46.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alnylam Pharmaceuticals (NASDAQ:ALNY) StockAlnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.Read More Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Stock News HeadlinesJanuary 30, 2023 | marketwatch.comLiposomal and Lipid Nanoparticle Drug Delivery Systems Market : Future Growth with Technology and Current Trends 2023 to 2028January 30, 2023 | marketwatch.comRNA Based Therapeutics Market Size 2023 with Economical Benchmarking, Old Statistics & Forecasts, Company Returns SharesJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 30, 2023 | americanbankingnews.comShort Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Increases By 11.2%January 28, 2023 | americanbankingnews.comFY2022 Earnings Estimate for Alnylam Pharmaceuticals, Inc. Issued By William Blair (NASDAQ:ALNY)January 27, 2023 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Post FY2025 Earnings of $3.01 Per Share, William Blair ForecastsJanuary 27, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Alnylam Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:ALNY)January 26, 2023 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Lowered to $143.00 at SVB LeerinkJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 24, 2023 | americanbankingnews.comShort Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Declines By 5.4%January 23, 2023 | marketwatch.comHaemophilia Treatment Market To Show Incredible Growth And Forecast By 2028 Segment, Privacy Tools And Key Players InformationJanuary 23, 2023 | marketwatch.comSickle Cell Disease Treatments Market Growth Insights 2023-2027 | Research by Manufacturers, Regions, Key Drivers and Demand ForecastJanuary 20, 2023 | markets.businessinsider.comNeedham Keeps Their Buy Rating on Cidara Therapeutics (CDTX)January 20, 2023 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated at Canaccord Genuity GroupJanuary 14, 2023 | nasdaq.comJuly 21st Options Now Available For Alnylam Pharmaceuticals (ALNY)January 13, 2023 | marketwatch.comOligonucleotide Therapeutics Market A Glimpse into the Potential Future OpportunitiesJanuary 11, 2023 | marketwatch.comAcute Hepatic Porphyria Drug Market New Innovations and Future Expansion 2023-2029 with Top Countries DataJanuary 9, 2023 | finance.yahoo.comAlnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22January 6, 2023 | finance.yahoo.com3 Growth Stocks That Could Rocket Higher in 2023January 5, 2023 | msn.comAlnylam Pharma director Amy Schulman assumes role of chair of the boardJanuary 5, 2023 | marketwatch.comPCSK9 Inhibitors Market 2023 : Growth Analysis, Key Stakeholders, Regional Outlook, End-User Applicants by 2028January 4, 2023 | finance.yahoo.comVERA Dips Despite Positive Data From IgA Nephropathy StudyJanuary 4, 2023 | marketwatch.comRNA Interference Technology Market Set to High Latest Developments, Growth Prospects 2023-2027 with Future Trends and Share AnalysisDecember 23, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Akero Therapeutics (AKRO)December 22, 2022 | marketwatch.comRNAi for Therapeutic Market Growth Strategies and Statistics 2023 | Global Industry Developments, and Competitive Landscape Forecast to 2029December 21, 2022 | msn.comIonis Pharmaceuticals begun at equalweight at Morgan Stanley on eplontersen launchDecember 21, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Wave Life Sciences (WVE)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Company Calendar Last Earnings10/27/2021Today1/30/2023Next Earnings (Estimated)2/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees1,665Year Founded2002Price Target and Rating Average Stock Price Forecast$239.84 High Stock Price Forecast$415.00 Low Stock Price Forecast$143.00 Forecasted Upside/Downside+6.6%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($9.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-852,820,000.00 Net Margins-123.02% Pretax Margin-122.83% Return on Equity-430.74% Return on Assets-33.91% Debt Debt-to-Equity Ratio3.85 Current Ratio3.48 Quick Ratio3.33 Sales & Book Value Annual Sales$844.29 million Price / Sales32.79 Cash FlowN/A Price / Cash FlowN/A Book Value$4.92 per share Price / Book45.74Miscellaneous Outstanding Shares123,030,000Free Float121,306,000Market Cap$27.68 billion OptionableOptionable Beta0.50 Social Links Key ExecutivesYvonne L. GreenstreetChief Executive Officer & DirectorAkshay K. VaishnawPresidentJeffrey V. PoultonChief Financial Officer & Executive Vice PresidentPushkal P. GargChief Medical Officer & EVP-Medical AffairsJames P. BilottaChief Information Officer & SVPKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNUnited TherapeuticsNASDAQ:UTHRRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsOregon Public Employees Retirement FundBought 20,020 shares on 1/26/2023Ownership: 0.016%Inspire Investing LLCBought 1,352 shares on 1/26/2023Ownership: 0.012%Strs OhioBought 312 shares on 1/26/2023Ownership: 0.003%Tokio Marine Asset Management Co. Ltd.Bought 201 shares on 1/26/2023Ownership: 0.002%Steel Peak Wealth Management LLCSold 1,047 shares on 1/25/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ALNY Stock - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price forecast for 2023? 19 analysts have issued 1 year target prices for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's stock price to reach $239.84 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2023? Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of the year. Since then, ALNY stock has decreased by 5.0% and is now trading at $225.87. View the best growth stocks for 2023 here. Are investors shorting Alnylam Pharmaceuticals? Alnylam Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 5,680,000 shares, an increase of 11.2% from the December 31st total of 5,110,000 shares. Based on an average daily trading volume, of 783,400 shares, the days-to-cover ratio is currently 7.3 days. View Alnylam Pharmaceuticals' Short Interest. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.51) by $0.21. The biopharmaceutical company had revenue of $187.63 million for the quarter, compared to the consensus estimate of $218.69 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 430.74% and a negative net margin of 123.02%. Alnylam Pharmaceuticals's revenue was up 49.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.18) earnings per share. What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $970.00M-$1.08 billion, compared to the consensus revenue estimate of $1.07 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). What is Alnylam Pharmaceuticals' stock symbol? Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY." Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (7.65%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), Allspring Global Investments Holdings LLC (0.03%), DNB Asset Management AS (0.02%), Oregon Public Employees Retirement Fund (0.02%) and Xponance Inc. (0.01%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alnylam Pharmaceuticals' stock price today? One share of ALNY stock can currently be purchased for approximately $225.87. How much money does Alnylam Pharmaceuticals make? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $27.79 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($9.77) on an earnings per share basis. How many employees does Alnylam Pharmaceuticals have? The company employs 1,665 workers across the globe. How can I contact Alnylam Pharmaceuticals? Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101. This page (NASDAQ:ALNY) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.